Combination Immunotherapy Shows High Activity Against Recurrent Hodgkin Lymphoma
NYU Langone HealthA new combination of three drugs that harness the body’s immune system is safe and effective, destroying most cancer cells in 95 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study.